Publications
Nightingale Health’s technology is routinely used in world-class epidemiological and genetic studies. There are over 450 publications that have utilized our technology.
All
Ageing
Bioinformatics
Cancer
Cardiovascular diseases
Drug development
Fatty liver disease
Gut microbiota
Human genetics
Kidney disease
Maternal health
Metabolic risk factors
Method description
Neurological diseases
Nutrition
T1D
T2D
Inflammation
Metabolic risk factors
A Metabolic Screen in Adolescents Reveals an Association Between Circulating Citrate and Cortical Bone Mineral Density
Kemp et al. J Bone Miner Res. 2019;18:e3697.
Metabolic risk factors
Substantial fat mass loss reduces low-grade inflammation and induces positive alteration in cardiometabolic factors in normal-weight individuals
Sarin et al. Scientific Reports 2019;9:3450
Drug development
Mendelian Randomization Study of ACLY and Cardiovascular Disease
Ference et al. N Engl J Med 2019;380:1033-1042
Lea et al. eLife 2019;8:e40538.
Metabolic risk factors
Increased High-Density Lipoprotein Levels Associated with Age-Related Macular Degeneration
Colijn et al. Ophthalmology 2019;126(3):393-406
Metabolic risk factors
Inflammation and hearing status in mid-childhood and mid-life: a population-based cross-sectional study
Wang et al. Int J Epidemiol. 2019 Pre-print
Michielsen et al. Mol Nutr Food Res. 2019;63(9):e1801095
Cardiovascular diseases
Coronary artery disease, genetic risk and the metabolome in young individuals
Battram et al. Wellcome Open Res 2019;3:114
Metabolic risk factors
Glycoprotein acetyls GlycA) at 12 months are associated with high-sensitivity C-reactive protein and early life inflammatory immune measures
Collier et al. Pediatr Res. 2019;85:584–85
Ahola-Olli et al. Diabetologia 2019; Pre-print
Metabolic risk factors
Metabolomics and Their Ability to Distinguish Thyroid Disorders: A Retrospective Pilot Study
Struja et al. Horm Metab Res 2019. doi: 10.1055/a-0850-9691
Mills et al. BMC Medicine 2019;17(1):15
Mefford et al. BioRxiv 2019; preprint
Neurological diseases
Serum GlycA level is a candidate biomarker for disease activity in systemic lupus erythematosus and for proliferative status of lupus nephritis, independent of renal function impairment
Dierckx et al. BioRxiv 2018; preprint
Metabolic risk factors
Biomarker Glycoprotein Acetyls Is Associated With the Risk of a Wide Spectrum of Incident Diseases and Stratifies Mortality Risk in Angiography Patients
Kettunen et al. Circulation: Genomic and Precision Medicine 2018:11;e002234.